Lewis y/b Hapten anticorps

N° du produit ABIN5564290

Cet anticorps anti-Lewis y/b Hapten Monoclonal Souris (Clone SC104) (ABIN5564290) détecte spécifiquement Lewis y/b Hapten dans ELISA, FACS, Func, ICC et IHC. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour Lewis y/b Hapten anticorps (ABIN5564290)

Antigène: Lewis y/b Hapten

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Application: ELISA, Flow Cytometry (FACS), Functional Studies (Func), Immunocytochemistry (ICC), Immunohistochemistry (IHC)

Clone: SC104

Détail du produit

Specificité: Recognizes human sialyltetraosylceramide. Does not bind to blood lympocytes, granulocytes, bone marrow progenitor cells, GM1, GD1a, GT1b or sialyl LewisX antigens.

Réactivité croisée: Humain

Pureté: >95 % (SDS-PAGE)

niveau d'endotoxine: <0.001EU/μg purified protein (LAL test, Lonza).

Immunogène: Tissue cultured colorectal tumor cell lines (C170, C146, Colo205 and JW).

Isotype: IgG1

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: Lot specific

Buffer: In PBS.

Agent conservateur: Without preservative

Stock: 4 °C,-20 °C

Stockage commentaire: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C.

Date de péremption: 12 months

Détail du antigène

Antigène: Lewis y/b Hapten

Autre désignation: Lewisy/b hapten

Sujet: Membrane glycolipids represent an unexplored source of tumor-associated antigens. Many of these are overexpressed and altered in tumors compared to normal tissue. Research into aberrant glycosylation and over-expression of glycolipids on the surface of the majority of cancers, coupled with a knowledge of glycolipids as functional molecules involved in a number of cellular physiological pathways, has provided a novel area of targets for cancer immunotherapy. Lewis-y/b is a cell surface carbohydrate blood group antigen expressed at very low levels in normal tissue, but often found to be overexpressed on breast, lung, colon and ovarian cancer cells. Clone SC104 recognizes a unique cell surface antigen sialyltetraosylceramide, expressed by 90 % of colorectal tumors at all clinical stages. SC104 targets colorectal cancer-associated glycolipids and induces tumor cell death in vitro independently of CDC or ADCC or blockade of known survival signaling pathways. It induces apoptotic cell death and synergizes with chemotherapy in vivo in mice.